IL152076A0 - A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines - Google Patents

A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines

Info

Publication number
IL152076A0
IL152076A0 IL15207601A IL15207601A IL152076A0 IL 152076 A0 IL152076 A0 IL 152076A0 IL 15207601 A IL15207601 A IL 15207601A IL 15207601 A IL15207601 A IL 15207601A IL 152076 A0 IL152076 A0 IL 152076A0
Authority
IL
Israel
Prior art keywords
migraines
acute
treatment
pain
pharmaceutical composition
Prior art date
Application number
IL15207601A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL152076A0 publication Critical patent/IL152076A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15207601A 2000-04-07 2001-03-16 A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines IL152076A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19573800P 2000-04-07 2000-04-07
PCT/IB2001/000391 WO2001076576A2 (en) 2000-04-07 2001-03-16 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines

Publications (1)

Publication Number Publication Date
IL152076A0 true IL152076A0 (en) 2003-05-29

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15207601A IL152076A0 (en) 2000-04-07 2001-03-16 A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines

Country Status (35)

Country Link
US (2) US20010036943A1 (pt)
EP (1) EP1272218B1 (pt)
JP (1) JP2003530345A (pt)
KR (1) KR20030040201A (pt)
CN (1) CN1468111A (pt)
AP (1) AP2002002642A0 (pt)
AR (1) AR027773A1 (pt)
AT (1) ATE291438T1 (pt)
AU (1) AU3768001A (pt)
BG (1) BG107138A (pt)
BR (1) BR0109837A (pt)
CA (1) CA2405142A1 (pt)
CR (1) CR6767A (pt)
CZ (1) CZ20023214A3 (pt)
DE (1) DE60109589T2 (pt)
EA (1) EA004930B1 (pt)
EE (1) EE200200579A (pt)
ES (1) ES2236185T3 (pt)
GT (1) GT200100055A (pt)
HU (1) HUP0301822A3 (pt)
IL (1) IL152076A0 (pt)
IS (1) IS6560A (pt)
MA (1) MA26889A1 (pt)
MX (1) MXPA02009817A (pt)
NO (1) NO20024734D0 (pt)
OA (1) OA12241A (pt)
PA (1) PA8515001A1 (pt)
PE (1) PE20011307A1 (pt)
PL (1) PL365957A1 (pt)
SK (1) SK13952002A3 (pt)
SV (1) SV2002000377A (pt)
TN (1) TNSN01053A1 (pt)
WO (1) WO2001076576A2 (pt)
YU (1) YU74602A (pt)
ZA (1) ZA200207996B (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
WO2002026020A2 (en) * 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
WO2002085843A2 (en) * 2001-04-20 2002-10-31 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
WO2002100434A1 (en) * 2001-06-07 2002-12-19 The General Hospital Corporation Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
CA2458375A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
CA2462453C (en) 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA04004373A (es) 2001-11-09 2004-08-11 Upjohn Co Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades.
WO2003049753A1 (en) * 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
HUP0500200A2 (hu) * 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
JP4428053B2 (ja) * 2002-02-05 2010-03-10 味の素株式会社 ガバペンチン若しくはプレガバリンおよびｎ型カルシウムチャンネル拮抗剤を含有する医薬組成物
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1480977A2 (en) 2002-02-15 2004-12-01 PHARMACIA & UPJOHN COMPANY Substituted aryl compounds for treatment of disease
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US20040014681A1 (en) * 2002-05-14 2004-01-22 Ralph Ryback Method for treating dermatoses and tissue damage
JP2006504634A (ja) * 2002-05-15 2006-02-09 アボット・ラボラトリーズ 神経障害性疼痛の治療
KR20060013632A (ko) 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
WO2004035041A1 (en) * 2002-10-17 2004-04-29 Novartis Ag Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
PT1578422E (pt) 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
BRPI0408131A (pt) * 2003-03-06 2006-03-01 Botulinum Toxin Res Ass Inc tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050085652A1 (en) * 2003-04-08 2005-04-21 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2540895C (en) * 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (hu) * 2003-12-19 2016-04-28 Pál Kocsis Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US8940311B2 (en) * 2004-10-21 2015-01-27 Tae-Hong Lim In situ controlled release drug delivery system
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
AU2005309586A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
WO2008010223A2 (en) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
JPWO2008020651A1 (ja) * 2006-08-17 2010-01-07 国立大学法人九州大学 Ｐ２ｘ４受容体アンタゴニスト
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
US20100048605A1 (en) * 2006-12-11 2010-02-25 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
MX2010002692A (es) 2007-09-13 2010-06-01 Concert Pharmaceuticals Inc Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
US20100312073A1 (en) * 2008-01-31 2010-12-09 David Yarnitsky Method of predicting pain medication efficacy
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
JP2014514248A (ja) * 2011-02-18 2014-06-19 ネステク ソシエテ アノニム 動物の神経系への損傷を治療、軽減、又は予防するための方法及び組成物
ES2387973B1 (es) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
CA2882038A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104758933A (zh) * 2014-10-29 2015-07-08 吴鑫欣 治疗神经卡压、神经瘤疼痛的药物和给药系统
WO2018175696A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018183320A1 (en) * 2017-03-31 2018-10-04 Depco, Inc. Therapeutic putty having analgesics and/or counterirritants
WO2018191480A1 (en) * 2017-04-12 2018-10-18 Synergistic Therapeutics. Llc Therapeutic neuropathic pain lotion
EP4467600A3 (en) * 2017-05-10 2025-03-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR101944113B1 (ko) 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) * 2022-03-21 2024-04-26 中山大学附属第三医院 一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937077B1 (en) * 1996-10-30 2006-05-17 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
CN1468111A (zh) 2004-01-14
JP2003530345A (ja) 2003-10-14
PE20011307A1 (es) 2001-12-28
CR6767A (es) 2004-06-09
YU74602A (sh) 2006-05-25
BR0109837A (pt) 2003-01-21
GT200100055A (es) 2001-12-31
EE200200579A (et) 2004-06-15
AU3768001A (en) 2001-10-23
AR027773A1 (es) 2003-04-09
NO20024734D0 (no) 2002-10-02
MA26889A1 (fr) 2004-12-20
US20010036943A1 (en) 2001-11-01
PL365957A1 (en) 2005-01-24
EP1272218B1 (en) 2005-03-23
WO2001076576A3 (en) 2002-06-20
CA2405142A1 (en) 2001-10-18
CZ20023214A3 (cs) 2003-11-12
WO2001076576A2 (en) 2001-10-18
EA004930B1 (ru) 2004-10-28
HUP0301822A2 (hu) 2003-11-28
AP2002002642A0 (en) 2002-12-31
HUP0301822A3 (en) 2005-06-28
OA12241A (en) 2004-01-27
US20030133951A1 (en) 2003-07-17
ES2236185T3 (es) 2005-07-16
TNSN01053A1 (fr) 2005-11-10
ZA200207996B (en) 2003-10-20
DE60109589T2 (de) 2005-09-01
PA8515001A1 (es) 2002-02-21
MXPA02009817A (es) 2003-03-27
EP1272218A2 (en) 2003-01-08
ATE291438T1 (de) 2005-04-15
SV2002000377A (es) 2002-07-03
BG107138A (en) 2003-05-30
KR20030040201A (ko) 2003-05-22
IS6560A (is) 2002-09-20
DE60109589D1 (de) 2005-04-28
EA200200910A1 (ru) 2003-02-27
SK13952002A3 (sk) 2003-12-02

Similar Documents

Publication Publication Date Title
IL152076A0 (en) A pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraines
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HU0103558D0 (en) Pharmaceutical composition for the treatment of stroke and traumatic brain insury
GB0117618D0 (en) Pharmaceutical dosage form
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
GB0012291D0 (en) Pharmaceutical combination
GB0020874D0 (en) Fluid treatment
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
GB2359073B (en) Fluid treatment
AU2002221510A1 (en) A pharmaceutical composition of chinese herbs for treating snuffle, headache and the use thereof
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
GB0012293D0 (en) Pharmaceutical combination
ZA200400480B (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes.
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
SI1408966T1 (sl) Sinergistične farmacevtske kombinacije za preprečevanje ali zdravljenje diabetesa
GB9921237D0 (en) Fluid treatment
GB0017666D0 (en) Pharmaceutical combination
GB0016426D0 (en) Pharmaceutical combination
GB9901651D0 (en) Treatment of fluid streams